In the title compound, [Pb2(C8H4O4)2(C19H12N4O)2]n·3.5nH2O (1), has been synthesized by the hydrothermal assembly of 1,4-benzenedicarboxylate and 4-(1H-1,3,7,8-tetraazacyclopenta[l]-phenanthren-2-yl)phenol(TCPP) ...In the title compound, [Pb2(C8H4O4)2(C19H12N4O)2]n·3.5nH2O (1), has been synthesized by the hydrothermal assembly of 1,4-benzenedicarboxylate and 4-(1H-1,3,7,8-tetraazacyclopenta[l]-phenanthren-2-yl)phenol(TCPP) with lead acetate. Elemental analysis, X-ray crystal structure analysis, IR spectrum, thermogravimetric analysis and luminescence property were carried out for the structural determination and characterization of the title compound. Compound 1 crystallizes in triclinic, space group P1 with a=1.013 54(10) nm, b=1.104 84(11) nm, c=1.210 05(12) nm, α=76.812 0(10)°, β=74.814 0(10)°, γ=86.030 0(10)°, V=1.273 1(2) nm3, Pb2C54H39N8O13.5, Mr=1 430.31, Z=1, Dc= 1.866 g·cm-3, μ=6.680 mm-1, F(000)=691, R=0.027 3 and wR=0.068 7 for 4 042 observed reflections (I>2σ(I)). The compound 1 exhibits two-dimensional network structures, which are further stacked through π-π interactions and hydrogen bonds to form three-dimensional supramolecular polymer. Solid-state luminescent spectrum of the compound 1 indicates intense fluorescent emission. CCDC: 748883.展开更多
目的：合成6‐氯／甲基‐2／3‐芳基喹喔啉衍生物，并测试其对SGC‐7901和HepG2肿瘤细胞增殖的抑制作用。方法以4‐氯／甲基邻苯二胺为起始原料，通过与草酸二乙酯环合、氯代、亲核取代反应合成6‐氯／甲基‐2／3‐芳基喹喔啉衍生物（3c...目的：合成6‐氯／甲基‐2／3‐芳基喹喔啉衍生物，并测试其对SGC‐7901和HepG2肿瘤细胞增殖的抑制作用。方法以4‐氯／甲基邻苯二胺为起始原料，通过与草酸二乙酯环合、氯代、亲核取代反应合成6‐氯／甲基‐2／3‐芳基喹喔啉衍生物（3c‐1～7m‐1），并用M T T法测试所得目标化合物的抗肿瘤活性。结果合成得到15个相应的目标化合物，通过IR和1 H NMR确认结构。此类化合物对SGC‐7901肿瘤细胞增殖抑制作用较 HepG2细胞强，6‐氯‐2／3‐芳基喹喔啉衍生物抗肿瘤活性多数大于6‐甲基‐2／3‐芳基喹喔啉衍生物。6‐氯‐2／3‐芳基喹喔啉衍生物（5c‐1）和6‐甲基‐2／3‐芳基喹喔啉衍生物（7m‐1）对 SGC‐7901细胞增殖抑制 IC50值分别为2．02和0．0016μg／mL。结论目标产物（5c‐1，7m‐1）对SGC‐7901肿瘤细胞增殖抑制活性好，可以进行结构优化，以期开发毒副作用小、耐受性好的新型抗肿瘤药物。展开更多
文摘In the title compound, [Pb2(C8H4O4)2(C19H12N4O)2]n·3.5nH2O (1), has been synthesized by the hydrothermal assembly of 1,4-benzenedicarboxylate and 4-(1H-1,3,7,8-tetraazacyclopenta[l]-phenanthren-2-yl)phenol(TCPP) with lead acetate. Elemental analysis, X-ray crystal structure analysis, IR spectrum, thermogravimetric analysis and luminescence property were carried out for the structural determination and characterization of the title compound. Compound 1 crystallizes in triclinic, space group P1 with a=1.013 54(10) nm, b=1.104 84(11) nm, c=1.210 05(12) nm, α=76.812 0(10)°, β=74.814 0(10)°, γ=86.030 0(10)°, V=1.273 1(2) nm3, Pb2C54H39N8O13.5, Mr=1 430.31, Z=1, Dc= 1.866 g·cm-3, μ=6.680 mm-1, F(000)=691, R=0.027 3 and wR=0.068 7 for 4 042 observed reflections (I>2σ(I)). The compound 1 exhibits two-dimensional network structures, which are further stacked through π-π interactions and hydrogen bonds to form three-dimensional supramolecular polymer. Solid-state luminescent spectrum of the compound 1 indicates intense fluorescent emission. CCDC: 748883.
文摘目的：合成6‐氯／甲基‐2／3‐芳基喹喔啉衍生物，并测试其对SGC‐7901和HepG2肿瘤细胞增殖的抑制作用。方法以4‐氯／甲基邻苯二胺为起始原料，通过与草酸二乙酯环合、氯代、亲核取代反应合成6‐氯／甲基‐2／3‐芳基喹喔啉衍生物（3c‐1～7m‐1），并用M T T法测试所得目标化合物的抗肿瘤活性。结果合成得到15个相应的目标化合物，通过IR和1 H NMR确认结构。此类化合物对SGC‐7901肿瘤细胞增殖抑制作用较 HepG2细胞强，6‐氯‐2／3‐芳基喹喔啉衍生物抗肿瘤活性多数大于6‐甲基‐2／3‐芳基喹喔啉衍生物。6‐氯‐2／3‐芳基喹喔啉衍生物（5c‐1）和6‐甲基‐2／3‐芳基喹喔啉衍生物（7m‐1）对 SGC‐7901细胞增殖抑制 IC50值分别为2．02和0．0016μg／mL。结论目标产物（5c‐1，7m‐1）对SGC‐7901肿瘤细胞增殖抑制活性好，可以进行结构优化，以期开发毒副作用小、耐受性好的新型抗肿瘤药物。
